International Journal of Nanomedicine (Nov 2011)
Electrostatic self-assembly of multilayer copolymeric membranes on the surface of porous tantalum implants for sustained release of doxorubicin
Abstract
Xinming Guo1,*, Muwan Chen1,2,*, Wenzhou Feng1,*, Jiabi Liang1, Huibin Zhao1, Lin Tian1, Hui Chao3, Xuenong Zou11Orthopaedic Research institute/Department of Orthopaedic Surgery, the First Affiliated Hospital and Department of Pharmacy, the Fifth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China; 2Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark; 3Ministry of Education Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering of Sun Yat-sen University, Guangzhou, People's Republic of China *The first three authors contributed equally to this work as co-first authorAbstract: Many studies in recent years have focused on surface engineering of implant materials in order to improve their biocompatibility and other performance. Porous tantalum implants have increasingly been used in implant surgeries, due to their biocompatibility, physical stability, and good mechanical strength. In this study we functionalized the porous tantalum implant for sustained drug delivery capability via electrostatic self-assembly of polyelectrolytes of hyaluronic acid, methylated collagen, and terpolymer on the surface of a porous tantalum implant. The anticancer drug doxorubicin was encapsulated into the multilayer copolymer membranes on the porous tantalum implants. Results showed the sustained released of doxorubicin from the functionalized porous tantalum implants for up to 1 month. The drug release solutions in 1 month all had inhibitory effects on the proliferation of chondrosarcoma cell line SW1353. These results suggest that this functionalized implant could be used in reconstructive surgery for the treatment of bone tumor as a local, sustained drug delivery system.Keywords: self-assembly, surface modification, tantalum, drug delivery system, doxorubicin, bone tumor